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Abstract
Background: Barrett's esophagus, a risk factor for esophageal adenocarcinoma, is associated with reflux disease.
The aim of this study was to assess the expression of bile acid receptors in the esophagus (normal, esophagitis,
Barrett's esophagus and adenocarcinoma) and to investigate their possible function.
Results: the expression of the bile acid receptors FXR and VDR in esophageal biopsies from patients with a
normal mucosa, esophagitis, Barrett's esophagus or adenocarcinoma (n = 6 per group) and in cell lines derived
from Barrett's esophagus and esophageal adenocarcinoma, was asses s e d  b y  r e a l  t i m e  Q - P C R  a n d
immunohistochemistry. The effect of guggulsterone, an antagonist of bile acid receptors, on apoptosis of Barrett's
esophagus-derived cells was assessed morphologically, by flow cytometry and by measuring caspase 3 activity.
The expression of FXR was increased in esophagitis, Barrett's esophagus and adenocarcinoma compared to
normal mucosa by a mean of 44, 84 and 16, respectively. Immunohistochemistry showed a weak expression in
normal esophagus, a strong focal reactivity in Barrett's esophagus, and was negative in adenocarcinoma. VDR
expression did not significantly differ between groups. In cell cultures, the expression of FXR was high in Barrett's
esophagus-derived cells and almost undetectable in adenocarcinoma-derived cells, whereas VDR expression in
these cell lines was not significantly different. In vitro treatment with guggulsterone was associated with a significant
increase in the percentage of apoptotic cells and of the caspase 3 activity.
Conclusion: the bile acid receptor FXR is significantly overexpressed in Barrett's esophagus compared to normal
mucosa, esophagitis and esophageal adenocarcinoma. The induction of apoptosis by guggulsterone in a Barrett's
esophagus-derived cell line suggests that FXR may contribute to the regulation of apoptosis.
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Background
Barrett's esophagus (BE), defined by the detection of
intestinal metaplasia in the esophagus at histological
examination [1], is the most important risk factor for
esophageal adenocarcinoma (AC) [2]. In subjects with BE
the annual incidence of esophageal AC is approximately
0.4–2.1% [3]. Prevailing theories link this type of cancer
to gastroesophageal reflux disease (GERD). The noxious
agents responsible for injuring the esophageal mucosa in
patients with GERD may originate from the stomach
(hydrochloric acid and pepsin) or the duodenum (bile
acids and pancreatic secretions). Mixed bile and acid
reflux is more harmful to the esophageal mucosa than
acid reflux alone in humans [4,5]. In an experimental rat
model, the creation of a duodenoesophageal anastomosis
led to esophagitis, intestinal metaplasia and eventually
esophageal AC [6], and biliary diversion did not lead to
regression of BE, but prevented AC [7]. Previous studies
have demonstrated that the transformation of BE into
esophageal AC is related to a loss of apoptotic mecha-
nisms [8]. However, the contribution of bile acid recep-
tors to the apoptotic processes in BE and esophageal AC is
unknown.
Bile acid receptors, including the farnesoid X receptor
(FXR) and the vitamin D receptor (VDR), have recently
been identified [9,10]. These transcription factors are
abundantly expressed in the liver and in the lower diges-
tive tract, where they regulate the homeostasis of choles-
terol and bile acids [11]. In the human colon, the
expression of FXR progressively decreases in the sequence
normal mucosa – adenoma – adenocarcinoma [12].
The observation that apoptosis may be triggered by gug-
gulsterone, a known FXR antagonist [13], suggests that
this compound may enhance apoptosis in tissues and
cells expressing this receptor. VDR is best known for main-
tenance of mineral homeostasis and bone architecture,
but its role as a mediator of apoptosis has been increas-
ingly recognised [14] in various types of cells. The expres-
sion and the possible function of bile acid receptors in the
esophagus and in particular in BE and esophageal AC is
unknown.
In this study we hypothesized that FXR and VDR are
expressed in the esophagus and may contribute to the reg-
ulation of apoptosis in intestinal metaplasia. To test this
hypothesis, we measured the expression of these receptors
by quantitative polymerase chain reaction (PCR) and
immunohistochemistry in esophageal samples from
patients with a normal esophagus, esophagitis, BE or AC,
as well as in cell lines derived from human BE and from
esophagus AC. Finally, we investigated in vitro a possible
role of esophageal bile acid receptors on apoptosis, using
FXR and VDR agonists and antagonists.
Results
Expression of FXR and VDR in tissue biopsies
There was an increase in the relative expression of FXR in
the sequence from normal esophagus (1 ± 0.83) to
esophagitis (44 ± 15, p = 7·10-5) and to BE in which this
receptor resulted most elevated (84 ± 36, p = 8·10-4). In
AC, the expression of FXR was inferior to that measured in
esophagitis and BE, but it was significantly superior to
that of normal esophagus (16 ± 9, p = 0.01) (Figure 1A).
The relative quantity of VDR mRNA was not significantly
different in normal esophagus (1 ± 0.67) compared to
esophagitis (0.78 ± 0.89, p = ns), BE (2.23 ± 1.62, p = ns)
and AC (0.97 ± 0.99, p = ns), suggesting a constitutive
expression of this receptor in these different esophageal
conditions (Figure 1B).
Expression of FXR and VDR in BE-derived and esophageal 
AC-derived cell lines
The expression of FXR was significantly higher in BE-
derived cells compared to AC-derived cells (1 ± 0.05 vs
9·10-4 ± 1·10-4, p = 3·10-6) (Figure 2A). This difference
suggests an almost complete loss of expression of FXR in
esophageal AC cells.
VDR expression was inferior in AC compared to BE cells,
although this difference did not reach statistical signifi-
cance (0.36 ± 0.02 vs 1 ± 0.28, p = 0.06), (Figure 2B).
Localisation of FXR by immunohistochemistry
In tissue samples of normal esophagus (Figure 3A) there
was a weak positive signal of the majority of cellular
nuclei, which was limited to the basal layer of the squa-
mous epithelium. The superficial epithelial layers and the
lamina propria were characterized by a negative staining.
In Barrett's esophagus (Figure 3B), there was a strongly
positive nuclear staining in some areas, while other meta-
plastic regions remained negative. The focally positive
areas were apparently randomly distributed in the crypts
and the positive cells were morphologically indistinguish-
able from those which did not stain. Tissue from dysplasia
(Figure 3C) or esophageal adenocarcinoma (Figure 3D)
resulted completely negative.
Induction of apoptosis
Treatment of the BE-derived cells with the FXR agonist
GW 4064 did not significantly affect the percentage of
apoptotic cells compared to untreated cells (9.5% ± 1.6%
vs. 6.9% ± 0.8%, p = ns; Figure 4A). On the other hand,
treatment with the FXR antagonist guggulsterone resulted
in an increased proportion of cells undergoing apoptosis
(15.1% ± 3.5% vs 6.9% ± 0.8%, p = 0.02; Figure 4A), with-
out any induction of necrosis, as assessed by flow cytom-
etry (Figure 5).Molecular Cancer 2006, 5:48 http://www.molecular-cancer.com/content/5/1/48
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VDR stimulation or inhibition by lithocholic acid or ZK
168281, respectively, did not significantly alter the pro-
portion of apoptotic cells (Figure 4B).
The significant proapoptotic effect of guggulsterone on
BE-derived cells (CP-18821) previously demonstrated by
flow cytometry was additionally verified by measuring the
caspase 3 activity. Guggulsterone treatment was associ-
ated with a significant induction of apoptosis compared
to untreated cells (177 ± 15 vs 53 ± 7; p = 7·10-4) as meas-
ured fluorometrically (Figure 6).
Finally, the induction of apoptosis was qualitatively
assessed by observing the morphological changes after
Relative expression of mRNA coding for FXR (2A) and VDR (2B) in cultures of cells derived from Barrett's esophagus (CP- 18821) and esophageal adenocarcinoma (OACP4C) Figure 2
Relative expression of mRNA coding for FXR (2A) and VDR (2B) in cultures of cells derived from Barrett's esophagus (CP-
18821) and esophageal adenocarcinoma (OACP4C).
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Relative expression of mRNA coding for FXR (1A) and VDR (1B) in esophageal biopsies from normal esophagus, esophagitis,  Barrett's esophagus and esophageal adenocarcinoma, n = 6 for each group Figure 1
Relative expression of mRNA coding for FXR (1A) and VDR (1B) in esophageal biopsies from normal esophagus, esophagitis, 
Barrett's esophagus and esophageal adenocarcinoma, n = 6 for each group.
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Representative immunohistochemistry images using a monoclonal FXR antibody on tissues from a normal esophagus (3A), Bar- rett's esophagus (3B), Barrett's esophagus and dysplasia (3C) and esophageal adenocarcinoma (3D) Figure 3
Representative immunohistochemistry images using a monoclonal FXR antibody on tissues from a normal esophagus (3A), Bar-
rett's esophagus (3B), Barrett's esophagus and dysplasia (3C) and esophageal adenocarcinoma (3D). Weakly stained nuclei 
were present in the basal layer of squamous epithelium in normal esophagus and a strong staining was observed in focal areas 
of Barrett's esophagus. Dysplasia and adenocarcinoma remained negative.Molecular Cancer 2006, 5:48 http://www.molecular-cancer.com/content/5/1/48
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treatment of cells with guggulsterone (Figure 7). A consid-
erable proportion of these cells showed shrinkage and
nuclear condensation (Figure 7B). Staurosporin induced
similar, but more pronounced changes (Figure 7C).
Discussion
We showed that the bile acid receptor FXR is significantly
more expressed in tissue biopsies from BE as compared to
normal esophageal mucosa. This is probably related to the
replacement of the normal squamous epithelium by intes-
tinal metaplasia in BE (FXR is abundantly expressed in
small and large intestine mucosa [15,16]), although the
role of other factors (e.g. age, gender) cannot be excluded.
Immunohistochemistry showed that FXR is weakly
present and limited to the nuclei of the basal cell layer in
normal esophagus. FXR was strongly present in BE, but its
distribution was focal, suggesting the presence of clusters
of cells in which this nuclear receptor was highly
expressed and others where FXR was absent, although
positive and negative cells were morphologically impossi-
ble to differentiate. Staining of tissues presenting dyspla-
sia or carcinoma was in all cases negative. These findings
Representative FACS diagrams of cells derived from Barrett's esophagus (CP-18821): without treatment (5A), treated with  guggulsterone (5B) and treated with sodium dodecyl-sulfate-treated (5C) Figure 5
Representative FACS diagrams of cells derived from Barrett's esophagus (CP-18821): without treatment (5A), treated with 
guggulsterone (5B) and treated with sodium dodecyl-sulfate-treated (5C). Zone 1 (Z 1): cells alive, Z 2: apoptotic cells. Z 3: 
necrotic cells.
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Percentages of apoptotic CP-18821 Barrett's esophagus-derived cells after treatment with FXR (4A) or VDR (4B) ligands, as  measured by flow cytometry Figure 4
Percentages of apoptotic CP-18821 Barrett's esophagus-derived cells after treatment with FXR (4A) or VDR (4B) ligands, as 
measured by flow cytometry.
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suggest that FXR may be a heterogeneous marker for Bar-
rett's metaplasia, but not dysplasia or adenocarcinoma.
The increase of FXR expression in biopsies from patients
with an esophagitis is an unexpected finding, because it is
not a columnar epithelium. A possible explanation is that
the presence of inflammation may enhance the expres-
sion of FXR. Esophagitis is a risk condition for the devel-
opment of Barrett's esophagus: the increase in FXR
expression may possibly occur prior to the metaplastic
changes from a squamous into a columnar epithelium.
FXR is a nuclear receptor activated by bile acids, in partic-
ular chenodeoxycholic acid, which are abundantly
present in bile, a component of refluxate in BE [5,6]. This
receptor has been suggested to play a role in the regulation
of apoptotic pathways [17], which are of particular rele-
vance in BE. Indeed, in BE, cells present a decreased capa-
bility of apoptosis compared to cells from esophageal
squamous epithelium. This is suggested to relate to an
increased expression of antiapoptotic proteins such as Bcl-
xl and Bcl-2, as well as a decrease in proapoptotic factors
such as Bax [8,18,19]. Avoidance of apoptosis is an impor-
tant mechanism in the multistep process which character-
izes the progression of BE towards AC [20]. As a
consequence, compounds capable of inducing apoptosis
in BE could be beneficial in decreasing the risk of malig-
nant degeneration.
Guggulsterone, a potent antagonist of FXR [21], signifi-
cantly induced apoptosis in BE-derived cells. A similar
induction of apoptosis by guggulsterone has been
reported in human cells derived from lung carcinoma and
Representative microscopy photographs showing normal  untreated Barrett's esophagus-derived cells (7A) and cell  shrinkage and condensation of nuclei in cells incubated with  guggulsterone (7B) or with staurosporin (7C), an inducer of  apoptosis Figure 7
Representative microscopy photographs showing normal 
untreated Barrett's esophagus-derived cells (7A) and cell 
shrinkage and condensation of nuclei in cells incubated with 
guggulsterone (7B) or with staurosporin (7C), an inducer of 
apoptosis.
7 A. Untreated
7 B. Guggulsterone
7 C. Staurosporin
Fluorometric measurement of caspase 3 activity in CP 18821  Barrett's esophagus-derived cells was significantly increased  after treatment with guggulsterone, compared to untreated  cells Figure 6
Fluorometric measurement of caspase 3 activity in CP 18821 
Barrett's esophagus-derived cells was significantly increased 
after treatment with guggulsterone, compared to untreated 
cells.
0
50
100
150
200
250
untreated cells guggulsterone
C
a
s
p
a
s
e
 
3
 
a
c
t
i
v
i
t
y
 
[
f
l
u
o
r
e
s
c
e
n
c
e
 
u
n
i
t
s
]
p = 0.0007
Untreated cells GuggulsteroneMolecular Cancer 2006, 5:48 http://www.molecular-cancer.com/content/5/1/48
Page 7 of 10
(page number not for citation purposes)
leukaemia. This has been attributed to a down regulation
of genes known to stimulate cell proliferation such as cyc-
lin D1 and c-myc, as well as to a decrease in gene products
involved in antiapoptotic pathways (Bcl-2, c-FLIP and sur-
vivin), suggesting that the stimulation of apoptosis might
be an effect of guggulsterone-mediated FXR inhibition
[13]. However, we cannot exclude that apoptosis in our
experiments was induced by other mechanisms. In fact,
guggulsterone, as a steroid receptor ligand [22], may also
have induced apoptosis of BE-cells by acting on these
receptors, but the distribution and regulation of steroid
receptors in normal esophagus and BE is not known.
When treated with the FXR agonist GW4064 (which is a
more potent agonist than chenodeoxycholic acid), BE-
derived cells disclosed a slight, not significant increase of
apoptosis. The use of FXR agonists as enhancers of apop-
tosis has been described in ovarian cancer cells [23] and
in vascular smooth muscle cells [24]. Our results are in
agreement with these findings, although the increase in
apoptosis observed in our experiments, which was statis-
tically not significant, may be due to a different sensitivity
to GW4064 of the cell line we used.
In esophageal biopsies from AC, in the corresponding cell
cultures (OACP 4C) and in surgical tissue samples, very
low levels of expression of FXR, compared to BE, were
detected by PCR and imunohistochemistry. This could be
due to the low grade of differentiation observed in our AC
tissue samples at histological examination, as well as to
the marked pleiomorphism of cell cultures, which is pos-
sibly associated with a loss of expression of FXR. Interest-
ingly, we previously observed a similar reduction in FXR
expression in colon adenoma and adenocarcinoma, com-
pared to normal colon mucosa [12], supporting the
hypothesis that FXR is down-regulated in poorly differen-
tiated tissues and cells of tumoral origin.
The expression of VDR was similar in the different groups
of patients, and VDR agonists/antagonists were not found
to significantly modify apoptosis. This suggests that VDR
is constitutively expressed and is not a major player in the
regulation of apoptosis in BE.
A limitation of this study is that cell cultures were contin-
uously exposed to guggulsterone at a neutral pH. Under
physiological conditions the human esophagus is
exposed to bile reflux for intermittent periods of time (in
the range of minutes) in association or not with acid
reflux. Nehra et al. reported total bile acid concentrations
of 180 μM and a percentage of time at pH<4 of 22% in the
esophagus of patients with BE during a 15-hour monitor-
ing study [4]. This drawback could be overcome by study-
ing apoptotic mechanisms of BE in an animal model [25]
treated with the compounds used in this study.
Conclusion
In summary, the results of this study indicate that the bile
acid receptor FXR is focally overexpressed in BE and that
treatment with guggulsterone, an FXR antagonist, signifi-
cantly enhances apoptosis in a human BE-derived cell
line. We conclude that FXR inhibition may represent a
novel therapeutic approach in BE and that this warrants in
vivo studies.
Methods
Patients
Esophageal tissue biopsies were obtained during upper
digestive endoscopy from 24 patients with a normal
esophagus, reflux esophagitis, BE or AC (n = 6 for each
group). Tissue samples were taken during endoscopy for
histological examination and additional tissue samples
were stored in RNAlater™ (Qiagen, Hombrechtikon, Swit-
zerland) and frozen at -70°C. For each patient, the diag-
nosis was confirmed histologically. Biopsies of BE
presented no or low-grade dysplasia and all AC were mod-
erately to poorly differentiated. The research protocol has
been approved by the Ethics Committee of Geneva Uni-
versity Hospital, and written informed consent was
obtained from all patients.
Table 1: Patients' characteristics
Normal esophagus 
(n = 6)
Reflux esophagitis 
(n = 6)
Barrett's esophagus 
(n = 6)
Esophagus adenocarcinoma 
(n = 6)
Age [years] 55 ± 7 50 ± 9 78 ± 3 79 ± 8
Male [%] 17 50 67 67
Reflux symptom index score 1.9 ± 0.9 3.8 ± 1.8 1.3 ± 1.2 1.5 ± 1
Proton pump inhibitor medication [%] 33 67 67 100
Smoker [%] 33 33 33 33
Alcohol intake >20 g/d [%] 17 67 50 33
Caucasian ethnicity [%] 100 100 100 100Molecular Cancer 2006, 5:48 http://www.molecular-cancer.com/content/5/1/48
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Patient's characteristics including the Reflux Symptom
Index Score [26] and intake of proton pump inhibitors
during the 7 days preceding endoscopy are shown in
Table 1.
Cell cultures
Primary cell cultures from BE (CP-18821) transduced
with a retrovirus containing the human catalytic subunit
of telomerase reverse transcriptase [27] were maintained
at 37°C in 5% CO2 atmosphere in MCDB 153 medium
supplemented with 5% fetal bovine serum, 0.4 μg/mL
hydrocortisone, 10-10 mol/L cholera toxin, 140 μg/mL
bovine pituitary extract, 20 μg/mL adenine, 5 μg/mL insu-
lin, 5 μg/mL transferrin, 5 μg/mL selenium (all from
Sigma, Buchs, Switzerland), 4 mmol/L glutamine, 20 ng/
mL epidermal growth factor, 100 U/mL penicillin, 100
μg/mL streptomycin and 0.25 μg/mL amphotericin B (all
from Gibco, Basel, Switzerland).
The human gastro-esophageal junction AC-derived cell
line OACP 4C [28] and the epithelial cell line derived
from human colorectal adenocarcinoma HT-29 (ECACC,
Salisbury, UK) were maintained at 37°C in 5% CO2
atmosphere in RPMI-1640 (Sigma) medium supple-
mented with 10% fetal bovine serum, 100 U/mL penicil-
lin and 100 μg/mL streptomycin (Gibco). HT-29 cells
served as a positive control for the quantitative real time
PCR [12].
RNA isolation, reverse transcription and quantitative PCR
Total RNA was extracted from tissue biopsies weighing 5-
10 mg using the RNeasy Mini Kit (Sigma) according to the
manufacturer's instructions. cDNA was synthesized from
1 μg total RNA with the Omniscript reverse transcriptase
(Qiagen), an RNAse inhibitor and random hexamers
(Promega, Wallisellen, Switzerland). A LightCycler system
(Roche, Basel, Switzerland) was used for real time PCR.
The relative quantification of gene expression was nor-
malized to the endogenous ribosomal 18S RNA. Amplifi-
cation was performed in a total volume of 10 μL
containing 5 μL of kit-supplied QuantiTect™ Master mix
2×, 0.5 μL of specific primer mix, 0.5 μL of QuantiProbe,
3 μL RNase-free water and 1 μL of cDNA sample.
The following primers were used for FXR gene amplifica-
tion: F 5'-GGACCATGAAGACCAGATT-3' and R 5'-
ATGCCCAGACGGAAGTTT-3', with a 5'-GCTATGTTCCT-
TCGTT-3' probe. The expression of VDR was measured
using the following primers: F 5'-TGACCCTGGA-
GACTTTGA-3' and R 5'-TCGCCTGAAGAAGCCTTT-3',
with a 5'-CTGTGGGGTGTGTGGA-3' probe. PCR amplifi-
cation curves were analyzed with the LightCycler Software
version 3.5.28.
Immunohistochemistry
Resection specimens of 8 patients with Barrett's carci-
noma, all containing normal esophagus, metaplasia, dys-
plasia and adenocarcinoma were stained. Four-
micrometer paraffin sections were dewaxed, and antigen
retrieval was performed in 10 mmol/L Tris-EDTA (pH 9)
buffer in a microwave oven for 20 minutes at 100°C.
Monoclonal mouse anti-human FXR/NR1H4 antibody
(R&D Systems, Oxon UK; clone A9033A; dilution: 1:50)
was applied for 1 hour at room temperature.
After washing, immunoreactivity was visualized with
Envision kit (Dako B.V., Heverlee, Belgium). The sections
were subsequently counterstained with Mayer hematoxy-
lin and evaluated under a light microscopy. As positive
control normal human colon was used and as negative
controls the primary antibody was omitted.
Assessement of apoptosis by flow cytometry and caspase 3 
activity assay
BE-derived cell cultures CP-18821 (6·104 cells/well) were
plated for 12 hours and incubated in the presence of spe-
cific ligands for 48 hours prior to flow cytometric analysis
to quantify the percentage of cells which had undergone
apoptosis. The following ligands were used: FXR agonist
GW4064 (GlaxoSmithKline, Research Triangle Park, USA)
at a final concentration of 5 μM, FXR antagonist guggul-
sterone (Steraloids, Newport, USA) at 20 μM, VDR agonist
lithocholic acid (Sigma) at 30 μM and VDR antagonist
ZK168281 (Schering, Berlin, Germany) at 1 μM.
Following treatment with ligands, BE cells were labelled
with 0.25 μg 7-amino-actinomycin D (7-AAD, BD Bio-
sciences, Switzerland) according to the manufacturer's
instructions. Flow cytometry acquisition of events was
performed using the CellQuest software with a FACScan
equipment (Becton Dickinson, Heidelberg, Germany). In
each cell suspension, acquisition was terminated when
10,000 events were analyzed. Debris were discriminated
from nonviable cells by a forward scatter (FSC)/FL-3 dot
plot in which FL-3 corresponded to 7-AAD-associated flu-
orescence. In this plot (forward scatter [FSC; x axis] versus
fluorescence [FL-3; y axis]), the combination of size and
DNA fluorescence criteria provides a rationale for discrim-
ination between debris and apoptotic cells. Fragments
with very low 7-AAD fluorescence were considered to be
cell debris with either no or very little DNA and were
excluded from cell gates [29].
Cell cultures treated with 2 μM staurosporine (Calbio-
chem, Luzern, Switzerland) for 24 hours served as positive
controls for apoptosis. The control for necrosis was
induced in cell cultures with 0.001% sodium dodecyl sul-
fate for 8 min before the assay (data not shown). Addi-
tionally, the 4',6-diamino-2-phenylindoleMolecular Cancer 2006, 5:48 http://www.molecular-cancer.com/content/5/1/48
Page 9 of 10
(page number not for citation purposes)
dihydrochloride (DAPI, Sigma) staining was used to con-
firm the induction of apoptosis: cells were fixed in 4%
paraformaldehyde for 20 min, incubated with DAPI 1 μg/
mL for 5 min and finally observed with a fluorescence
microscope.
To confirm the data on apoptosis issued from the FACS
analysis, the activity of caspase 3 was measured in cell cul-
tures exposed to guggulsterone for 8 hours with a fluoro-
metric immunosorbent enzyme assay kit (Roche)
according to the manufacturer's instructions.
Statistics
Data are presented as mean ± SD. All measurements were
performed in triplicate. Comparisons between groups
were performed using the Student's t-test. A p value ≤ 0.05
was considered statistically significant.
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